Publications by authors named "Jonathan Hebb"

Claim this Profile
T
Targeting CD137 enhances the efficacy of cetuximab.
Holbrook E Kohrt, A Dimitrios Colevas, Roch Houot, Kipp Weiskopf, Matthew J Goldstein, Jonathan Hebb

J Clin Invest· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.
Jonathan P O Hebb, Adriane R Mosley, Felipe Vences-Catalán, Narendiran Rajasekaran, Anna Rosén

Cancer Immunol Immunother· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targets, Toxins, and T Cells--a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas.
Jonathan Hebb, Holbrook Kohrt

Curr Hematol Malig Rep· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting CD137 enhances the efficacy of cetuximab.
Holbrook E Kohrt, A Dimitrios Colevas, Roch Houot, Kipp Weiskopf, Matthew J Goldstein, Jonathan Hebb

J Clin Invest· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients.
Jonathan Hebb, Sarit Assouline, Caroline Rousseau, Pierre Desjardins, Stephen Caplan

Cancer Chemother Pharmacol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis